NEW YORK and HAIKOU, China, April 29 /Xinhua-PRNewswire-FirstCall/ -- China Pharma Holdings, Inc. (“China Pharma”) which develops, manufactures, and markets generic and branded bio-pharmaceutical products in China, today pre-announced growth in excess of 60% for its First Quarter 2008 revenue and net income compared to First Quarter of 2007. The Company will release its First Quarter 2008 financial results on Monday, May 5, 2008 and host an earnings conference call at 10:00 a.m. EDT on Tuesday, May 6, 2008 to discuss these results.
Ms. Zhilin Li, President and CEO of China Pharma Holdings, Inc., Mr. Xinhua Wu, Chief Financial Officer, and Mr. Alan Sheinwald, Partner of HC International will be hosting the call. To participate in the conference call, please dial 1-800-591-6942 ten minutes prior to the scheduled conference call time. International callers should dial 1-617-614-4909. The conference pass code is 32765641.
About China Pharma Holdings, Inc.
China Pharma Holdings, Inc. develops, manufactures, and markets generic and brand bio-pharmaceutical products in China that treat a wide range of conditions, including infections, hepatitis, cardiovascular and CNS diseases, and other prevailing diseases. Helpson Bio-pharmaceutical Co., Ltd (Helpson), a specialty pharmaceutical company headquartered in Haikou City, Hainan province in China, is a wholly owned subsidiary of China Pharma Holdings. For more information about China Pharma Holdings, Inc., please visit http://www.chinapharmaholdings.com .
Safe Harbor Statement:
Certain statements in this press release and oral statements made by China Pharma on its conference call in relation to this release, constitute forward- looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as unanticipated changes in product demand, increased competition, failure to obtain or maintain intellectual property protection, downturns in the Chinese economy, uncompetitive levels of research and development, failure to obtain regulatory approvals, and other information detailed from time to time in the Company’s filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the company’s expectations.
CONTACT: Sophia Yu of China Pharma Holdings, Inc., +86-898-6681-1730, or
hps@chinapharmaholdings.com; Or Alan Sheinwald of HC International, Inc.,
+1- 914-669-0222, or Alan.sheinwald@hcinternational.net
Web site: http://www.chinapharmaholdings.com/
